RealWorld Dynamix™: Biologic and Otezla Switching in PsA 2017

Spherix Global Insights has released the 2017 update of RealWorld Dynamix: PsA based on analysis of 1,008 PsA patient charts. The large scale chart audit was completed by about 200 rheumatologists and focuses on patients that have been switched between biologic brands and/or Otezla during the past three months. In addition to comparisons from the

RealTime Dynamix™: Atopic Dermatitis Q2 2017

With two new entrants in the shape of Pfizer’s Eucrisa and Dupixent from Sanofi/Regeneron, the first ever biologic approved for atopic dermatitis (AD), the AD market is entering a period of real change. Just published RealTime Dynamix: Atopic Dermatitis Q2 2017 from Spherix Global Insights provides key insights on the shifting AD market. Click the

RealTime Dynamix™: Rheumatoid Arthritis EU Q1 2017

With the recent approval of two new JAK inhibitors and the imminent introduction of additional IL-6 inhibitors, EU rheumatologists anticipate substantial practice shifts in RA management. Spherix Global Insights recently released data collected from 257 rheumatologists in France, Germany, Italy, Spain and the UK, revealing a high unmet need for small molecules and alternate mechanism

RealTime Dynamix™: Bone and Mineral Metabolism Q1 2017

This Spherix Global Insights report highlights responses from 201 nephrologists surveyed in March 2017. Nephrologists provided feedback about changes in the hyperphosphatemia space as well as sharing thoughts about recent renal product approvals—Amgen’s Parsabiv and Opko’s Rayaldee. Click the button below to download highlights from this report. RTD: Bone and Mineral Metabolism

RealTime Dynamix: Humira in Immunology Q1 2017

Is AbbVie “Immune” to the Threats? Despite an onslaught of new mechanism drugs introduced in the leading autoimmune and inflammatory conditions over the past year, AbbVie’s Humira holds strong! Spherix Global Insights RealTime Dynamix reports in Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Crohn’s and Ulcerative Colitis and Atopic Dermatitis cover the market dynamics that impact Humira